<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Exhibit 99.1
of the Company's Current Report on Form 8-K dated June 12, 1998 for the period
ended December 31, 1995 restated to reflect the combined results of Incyte
Pharmaceuticals, Inc. and Synteni, Inc. and is qualified in its entirety by
reference to such Form 8-K.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               DEC-31-1995
<CASH>                                          10,584
<SECURITIES>                                    30,634
<RECEIVABLES>                                    7,643
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                49,619
<PP&E>                                          12,440
<DEPRECIATION>                                   3,297
<TOTAL-ASSETS>                                  58,892
<CURRENT-LIABILITIES>                           10,604
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            21
<OTHER-SE>                                      47,585
<TOTAL-LIABILITY-AND-EQUITY>                    58,892
<SALES>                                              0
<TOTAL-REVENUES>                                12,299
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                19,272
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (9,937)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (9,937)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (9,937)
<EPS-PRIMARY>                                   (0.53)
<EPS-DILUTED>                                   (0.53)